Thursday, October 15, 2026

How We Source Explore Search

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· February 22, 2026

They Plan To Sell Their Car And Buy 0.15 BTC As A Bet For The Future. The Response They Got? 'Just Keep The Car' If It's Only Worth $10K

View original at finance.yahoo.com

They Plan To Sell Their Car And Buy 0.15 BTC As A Bet For The Future. The Response They Got? 'Just Keep The Car' If It's Only Worth $10K Bitcoin (CRYPTO: BTC) has dropped around 28% over the past month, falling to roughly $68,000 on Wednesday…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

$250k Bitcoin within 10 years is not a pipe dream
80% confidence
Reddit commenter sold $180k worth of bank shares and put it into bitcoin in 2016
80% confidence
Reddit commenter sold 2 houses for Bitcoin and considers it best decision ever made
80% confidence
Bitcoin is going up and to the right forever against all fiat currencies
80% confidence
Nobody who has ever held bitcoin longer term has lost money on it
80% confidence
Reddit user planning to sell car worth $10,000 to buy 0.15 BTC
80% confidence

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones

October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,377 source documents archived

Query this data → isubstrate.com